SCHEMBL464172

SCHEMBL464172

COC(=O)[C@@H](NC(=O)[C@H](NC(=O)OC(C)(C)C)C1CCCCC1)C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 3/20 0.47
▸ GAA P10253 1/20 0.42
▸ HDAC4 P56524 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ CTSS P25774 2/20 0.40
▸ CTSK P43235 2/20 0.40
▸ REN P00797 2/20 0.39
▸ EPHX1 P07099 1/20 0.39
▸ CA12 O43570 1/20 0.38
▸ CA14 Q9ULX7 1/20 0.38
▸ CACNA1B Q00975 1/20 0.36
▸ MMP1 P03956 1/20 0.35
▸ MMP8 P22894 1/20 0.35
▸ ADAM17 P78536 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA7 P43166 1/20 0.35
▸ BTK Q06187 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12011278 1.00 AAK1 (0.47) AAK1GAAHDAC4HDAC1HDAC6
SCHEMBL13092001 1.00 AAK1 (0.47) AAK1GAAHDAC4HDAC1HDAC6
SCHEMBL464271 0.99 AAK1 (0.48) AAK1GAAHDAC4HDAC1HDAC6
SCHEMBL12435203 0.88 AAK1 (0.46) AAK1GAAHDAC4HDAC1HDAC6
SCHEMBL12658445 0.86 AAK1 (0.48) AAK1GAAHDAC4HDAC1HDAC6
SCHEMBL1372065 0.85 AAK1 (0.48) AAK1GAAHDAC4HDAC1HDAC6
SCHEMBL21904477 0.85 AAK1 (0.48) AAK1GAAHDAC4HDAC1HDAC6
SCHEMBL1372066 0.85 AAK1 (0.48) AAK1GAAHDAC4HDAC1HDAC6
SCHEMBL3048373 0.85 AAK1 (0.45) AAK1GAAHDAC4HDAC1HDAC6
SCHEMBL2098572 0.85 AAK1 (0.45) AAK1GAAHDAC4HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140294763-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2014-10-02 — — US disclosed
US-8529882-B2 Peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-10 — — US disclosed
US-20120282219-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-11-08 — — US disclosed
US-20120064034-A1 Peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140294763-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS CTSC, PREP, PEPD AAK1 3561/4885GAA 331/4885HDAC4 4093/4885
US-20120064034-A1 Peptidomimetic protease inhibitors CTSC, PREP, PEPD AAK1 3561/4885GAA 331/4885HDAC4 4093/4885
US-20120282219-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS CTSC, PEPD, PREP AAK1 3217/4885GAA 201/4885HDAC4 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback